Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical and Translational Oncology
Erschienen in: Clinical and Translational Oncology 6/2017

04.01.2017 | Review Article

Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it

verfasst von: M. Drizou, E. A. Kotteas, N. Syrigos

Erschienen in: Clinical and Translational Oncology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Anaplastic lymphoma kinase (ALK) rearrangement is detected in 3–7% of patients with non-small-cell lung cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the treatment of ALK-positive lung cancer. Despite the initial enthusiasm, most of the patients develop resistance within the first year of treatment. The main mechanisms are secondary mutations and bypass track activation. Moreover, crizotinib has low penetration into the central nervous system. The need to overcome these limitations has led to the development of second-generation inhibitors that have better effectiveness against crizotinib-resistant mutations and brain metastases. Ceritinib and alectinib are the only approved drugs of this group. Many ongoing trials try to define the most appropriate agent for the treatment of ALK-positive lung cancer depending on the responsible mechanism. This review focuses on the current data regarding the potential mechanisms of resistance to ALK inhibitors and the strategies to overcome it.
Literatur
1.
2.
Siegel RL, Miller KD, Jemal A. Cancer statistics 2016. Ca Cancer J Clin. 2016;66:7–30.
3.
Ettinger D, Wood D, Akerley W, Bazhenova L, Borghaei H, Camidge DR et al. Non-small-cell lung cancer, Version 6.2015. Featured updates to the NCCN guidelines. JNCCN. 2015;13(5):517–21.
4.
Candarella S, Johnson B. The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med. 2013;188(7):770–5.CrossRef
5.
Awad M, Shaw AT. ALK inhibitors in non-small-cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014;12(7):429–39.PubMedPubMedCentral
6.
7.
Van der Wekken AJ, Saber A, Hiltermann TJN, Kok K, Van den Berg A, Groen HJM. Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature. Crit Rev Oncol/Hematol. 2016. doi:10.​1016/​j.​critrevonc.​2016.​01.​024.
8.
Lovly C, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res. 2014;20(9):2249–56.CrossRefPubMedPubMedCentral
9.
Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell. 2016;73:1209–24.
10.
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281–4.CrossRefPubMed
11.
12.
Webb T, Slavish J, George RE, Look AT, Xue L, Jiang Q, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009;9(3):331–56.CrossRefPubMedPubMedCentral
13.
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.CrossRefPubMed
14.
15.
Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–53.CrossRefPubMedPubMedCentral
16.
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–59.
17.
Toyokawa G, Seto T, Takenoyama M, Ichinose Y. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev. 2015;34:797–805.CrossRefPubMedPubMedCentral
18.
Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancers. Lung Cancer. 2015;88(1):108–11.CrossRefPubMedPubMedCentral
19.
Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6(12):3314–22.CrossRefPubMed
20.
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.CrossRefPubMedPubMedCentral
21.
Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase I study. Lancet Oncol. 2012;13(10):1011–9.CrossRefPubMedPubMedCentral
22.
Crino L, Kim DW, Riely GJ, Janne PA, Blackhall FH, Camidge DR, et al. Initial phase 2 results with crizotinib in advanced ALK-positive non-small-cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol. 2011;29:7514.CrossRef
23.
Ou SHI, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small-cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist. 2012;17:1351–75.CrossRefPubMedPubMedCentral
24.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.CrossRefPubMed
25.
Solomon B, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.CrossRefPubMed
26.
27.
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015;10:S1–63.CrossRefPubMedPubMedCentral
28.
Ye M, Zhang X, Li N, Zhang Y, Jing P, Chang N, et al. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. Oncotarget. 2016;7(11):12289–304.PubMedPubMedCentral
29.
Choi YL, Soda M, Yamashita Y, Toshihide U, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363:1734–9.CrossRefPubMed
30.
Camidge DR, Doebele RC. Treating ALK-positive lung cancer- early success and future challenges. Nat Rev Clin Oncol. 2012;9(5):267–77.CrossRef
31.
Toyokawa G, Seto T. Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data. Oncol Res Treat. 2015;38:291–8.CrossRefPubMed
32.
Sullivan I, Planchard D. ALK inhibitors in non-small-cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016;8(1):32–47.PubMedPubMedCentral
33.
Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29:e443–5.CrossRefPubMed
34.
Rolfo C, Passiglia F, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, et al. ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res. 2014;3(4):250–61.PubMedPubMedCentral
35.
Steuer C, Ramalingam S. ALK positive non-small cell lung cancer, mechanisms of resistance and emerging treatment options. Cancer. 2014;120:2392–402.CrossRefPubMed
36.
Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71:6051–60.CrossRefPubMedPubMedCentral
37.
Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon B, Halmos B, et al. Mechanisms of acquired Crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4:120ra17.CrossRefPubMedPubMedCentral
38.
Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18:1472–82.CrossRefPubMedPubMedCentral
39.
Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, et al. The neuroblastoma associated F1174L mutation causes resistance to an ALK kinase inhibitor in ALK translocated cancers. Am Assoc Cancer Res. 2010. doi:10.​1158/​0008-5472.​CAN-10-2956.
40.
Heuckmann JM, Holzel M, Sos ML, Heynck S, Balke-Want H, Koker M, et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res. 2011;17(23):7394–401.CrossRefPubMedPubMedCentral
41.
Maione P, Sacco PC, Sgambato A, Casaluce F, Rossi A, Gridelli C. overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. Ther Adv Med Oncol. 2015;7(5):263–73.CrossRefPubMedPubMedCentral
42.
Isozaki H, Takigawa N, Kiura K. Mechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancer. Cancers. 2015;7:763–83.CrossRefPubMedPubMedCentral
43.
Yamaguchi N, Lucena-Araujo AR, Nakayama S, Figueiredo-Pontes L, Gonzalez DA, Yasuda H, et al. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the TKI crizotinib in ALK rearranged lung cancer. Lung Cancer. 2014;83(1):37–43.CrossRefPubMed
44.
45.
Tanizaki J, Okamoto I, Okabe T. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res. 2012. doi:10.​1158/​1078-0432.PubMed
46.
Cha YJ, Cho BC, Kim HR, Lee HJ, Shim HS. A case of ALK-rearranged adenocarcinoma with small cell carcinoma-like transformation and resistance to crizotinib. J Thorac Oncol. 2015;11(5):e55–8.CrossRefPubMed
47.
Nix N, Brown K. Ceritinib for ALK-rearrangement-positive non-small-cell lung cancer. J Adv Pract Oncol. 2015;6:156–60.PubMedPubMedCentral
48.
Raedler L. Zykadia (ceritinib) approved for patients with crizotinib-resistant ALK-positive non-small cell lung cancer. Am Health Drug Benef. 2015;8:163–6.
49.
Khozin S, Blumenthal GM, Zhang L, Tang S, Brower M, Fox E, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Am Assoc Cancer Res. 2015. doi:10.​1158/​1078-0432.​CCR-14-3157.
50.
Shaw AT, Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189–97.CrossRefPubMedPubMedCentral
51.
Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge R, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452–63.CrossRef
52.
Mok T, Spiegel D, Felip E, deMarinis F, Ahn MJ, Groen HJM, et al. ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients with ALK-rearranged(ALK+) non-small cell lung cancer previously treated with chemotherapy and crizotinib. J Clin Oncol. 2015;33:8059.
53.
Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Nishio M, et al. ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib ALKi-naïve adult patients with ALK-rearranged (ALK+) non-small cell lung cancer. J Clin Oncol. 2015;33:8060.
54.
El-Osta H, Shackelford R. Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for ceritinib. Pharmacogen Pers Med. 2015;8:145–54.
55.
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small-cell lung cancer. Cancer Discov. 2014;4:662–73.CrossRefPubMedPubMedCentral
56.
Toyokawa G, Inamasu E, Shimamatsu S, Yoshida T, Nosaki K, Hirai F, et al. Identification of a novel ALK G1123S mutation in a patient with ALK rearranged NSCLC exhibiting resistance to ceritinib. J Thorac Oncol. 2015;10(7):55–7.CrossRef
57.
Dong X, Fernandez-Salas E, Li E, Wang S. Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non-small-cell lung cancer cells. Neoplasia. 2016;18(3):162–71.CrossRefPubMedPubMedCentral
58.
Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, et al. P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. EBioMedicine. 2016;3:54–66.CrossRefPubMed
59.
Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, et al. Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015;8:17.CrossRefPubMedPubMedCentral
60.
Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G, et al. FDA approval: alectinib for the treatment of metastatic ALK positive non-small cell lung cancer following crizotinib. Clin Cancer Res. 2016. doi:10.​1158/​1078-0432.​CCR-16-1293.PubMed
61.
62.
Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al. Alectinib for patients with ALK-rearranged advanced non-small-cell lung cancer (AF 001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013;14:590–8.CrossRefPubMed
63.
Tamura T, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, et al. Updated data of a phase 1-2 study (AF001JP) of alectinib, a CNS-penetrant, highly selective ALK inhibitor in ALK-rearranged advanced NSCLC. Radiat Oncol. 2014;90:S6.
64.
Ou SHI, Ahn JS, De Petris L, Govindan R, Yang JCH, Hughes B, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2015;33:1–8.
65.
Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2015;17(2):234–42.CrossRef
66.
Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, et al. Two novel ALK mutations mediate acquired resistance to the next generation ALK inhibitor alectinib. Clin Cancer Res. 2014. doi:10.​1158/​1078-0432.​CCR-14-1511.
67.
Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ. ALK, F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. Lung Cancer. 2016;91:70–2.CrossRefPubMed
68.
Ou SHI, Azada M, Hsiang DJ, Herman JM, Kain TS, Siwak-Tapp C, et al. Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to Alectinib in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014;9:549–53.CrossRef
69.
Toyokawa G, Seto T, Takenoyama M, Ichinose Y. Crizotinib can overcome acquired resistance to CH5424802. Is amplification of the MET gene a key factor? J Thorac Oncol. 2014;9(3):e27–8.CrossRef
70.
Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, et al. Protocol design for the bench to bed trial in alectinib-refractory non-small-cell lung cancer patients harboring the EML4-ALK fusion gene (ALRIGHT/OLCSG1405). Clin Lung Cancer. 2016. doi:10.​1016/​j.​cllc.​2016.​05.​005.PubMed
71.
Fujita S, Masago K, Katakami N, Yatabe Y. Transformation to SCLC after treatment with the ALK inhibitor alectinib. J Thorac Oncol. 2016;11(6):e67–72.CrossRefPubMed
72.
Romanidou O, Landi L, Cappuzzo F, Califano R. Overcoming resistance to first/second generation EGFR TKIs and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Ther Adv Med Oncol. 2016;8:176–87.
73.
Ou SHI, Janne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 2014;25(2):415–22.CrossRefPubMed
74.
75.
Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. Safety and activity of Alectinib against systemic disease and brain metastases in patients with Crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF 002JG): results from the dose finding portion of a phase 1–2 study. Lancet Oncol. 2014;15:1119–28.CrossRefPubMed
76.
Kim YH, Ozasa H, Nagai H, Sakamori Y, Yoshida H, Yagi Y, et al. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol. 2013;8(9):85–6.CrossRef
77.
Felip E, Crino L, Kim DW, Spigel DR, Nishio M, Mok T, et al. Whole body and intracranial efficacy of ceritinib in patients with crizotinib pretreated, ALK-rearranged non-small-cell lung cancer and baseline brain metastases. Results from ASCEND-1 and ASCEND-2 trials. J Thorac Oncol. 2016;11:S57–166.
78.
Ou SH, Shaw AT, Govindan R, Socinski M, Camidge R, De Petris L, et al. Pooled analysis of CNS response to alectinib in two studies of pre-treated ALK+ NSCLC. 16th WCLC-IACLC. 2015.
79.
Gainor JF, Chi AS, Logan J, Hu R, Oh KS, Brastianos PK, et al. Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive NSCLC relapsing on standard dose alectinib. J Thorac Oncol. 2015;11(2):256–60.CrossRefPubMedPubMedCentral
80.
Gainor J, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015;10(2):232–6.CrossRefPubMedPubMedCentral
81.
Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Shinkel AH. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014;134:1484–94.CrossRefPubMed
82.
Johung KL, Yeh N, Desai NB, Williams TM, Lautenshlaeger T, Arvold ND, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol. 2015;34(2):123–9.CrossRefPubMedPubMedCentral
83.
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, et al. Local ablative therapy of oligoprogessive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–14.CrossRefPubMedPubMedCentral
84.
Squillace RM, Anjum R, Miller D, Vodala S, Moran L, Wang F, et al. AP 26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions. Cancer Res. 2013;73:5655.CrossRef
85.
86.
Facchinetti F, Tiseo M, Di Maio M, Graziano P, Bria E, Rossi G, et al. Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. Transl Lung Cancer Res. 2016;5(3):301–21.CrossRefPubMedPubMedCentral
87.
Liao BC, Lin CC, Shih JY, Yang JCH. Treating patients with ALK-positive non-small-cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol. 2015;7(5):274–90.CrossRefPubMedPubMedCentral
88.
Li T, LoRusso P, Maitland ML, Ou SHI, Bahceci E, Ball HA, et al. First-in-human, open-label dose escalation and dose expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. J Hematol Oncol. 2016;9:23.CrossRefPubMedPubMedCentral
89.
Reckamp KL, Infante JR, Blumenschein GR, Wakelee HA, Carter CA, Gockerman JP, et al. Phase I/II trial of X-396, a novel anaplastic lymphoma kinase inhibitor, in patients with ALK+ non-small-cell lung cancer. J Thorac Oncol. 2016;11(2):S36–7.CrossRef
90.
91.
Wang W, Jiang X, Song Z, Zhang Y. Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-TKI. OncoTargets Ther. 2016;9:211–5.CrossRef
92.
Lovly CM, Mc Donald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer. Nat Med. 2014;20(9):1027–34.CrossRefPubMedPubMedCentral
93.
Tan DSW, Araujo A, Zhang J, Signorovitch J, Zhou ZY, Cai X, et al. Comparative efficacy of ceritinib and crizotinib as initial ALK-targeted therapies in previously treated advanced NSCLC: an adjusted comparison with external controls. J Thorac Oncol. 2016;11(9):1550–7.CrossRefPubMed
Metadaten
Titel
Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it
verfasst von
M. Drizou
E. A. Kotteas
N. Syrigos
Publikationsdatum
04.01.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 6/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1605-y

Weitere Artikel der Ausgabe 6/2017

Clinical and Translational Oncology 6/2017 Zur Ausgabe

Special Article

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

Research Article

Nasopharyngeal carcinoma: 30-year experience of a single institution in a non-endemic area

Research Article

miR-26a-5p suppresses tumor metastasis by regulating EMT and is associated with prognosis in HCC

Research Article

Role of axillary ultrasound, magnetic resonance imaging, and ultrasound-guided fine-needle aspiration biopsy in the preoperative triage of breast cancer patients

Research Article

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

Review Article

Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Krebspatienten impfen: Was? Wen? Und wann nicht?

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Müde im Alter? Auch an die Nebenniere denken
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen